Search results for "Walk test"

showing 10 items of 26 documents

Determinants of CAT (COPD Assessment Test) scores in a population of patients with COPD in central and Eastern Europe: The POPE study

2019

Abstract Background The COPD Assessment Test (CAT) has been proposed to help guide therapy in chronic obstructive pulmonary disease (COPD). It is important to understand the distribution of scores in different COPD populations and their determinants. Methods The POPE study is an international, observational cross-sectional study of COPD subjects in 11 Central and Eastern European countries aimed at characterizing COPD phenotypes. Here we report the analysis of CAT scores with the objective of identifying their determinants, evaluating symptom load and investigating the distribution of scores among the participating countries. Additionally, we investigated the discrepancies between the CAT a…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationWalk TestComorbiditySeverity of Illness IndexPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineForced Expiratory VolumeInternal medicinePrevalencemedicineHumansEurope Eastern030212 general & internal medicineBulgariaTrial registrationeducationDepression (differential diagnoses)AgedHungaryeducation.field_of_studyCOPDDepressionbusiness.industryMiddle AgedExercise capacitymedicine.diseaseRespiratory Function Tests3. Good healthEastern europeanCross-Sectional Studies030228 respiratory systemPhysical EnduranceCopd assessment testFemaleObservational studySymptom AssessmentbusinessRespiratory Medicine
researchProduct

Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.

2022

Purpose Only a few studies are available on dose-related effects of sacubitril/valsartan (angiotensin receptor neprilysin inhibition (ARNI)) in real-life patients with heart failure and reduced ejection fraction (HFrEF). We sought to investigate clinical and functional effects in real-life HFrEF patients receiving ARNI at a different cumulative dose. Methods This was an observational study in consecutive outpatients admitted for HFrEF from October 2017 to June 2019. The PARADIGM criteria were needed for enrolment. ARNI was uptitrated according to blood pressure, drug tolerability, renal function and kaliemia. At least 10-month follow-up was required in each patient. Clinical assessment, Kan…

Malemedicine.medical_specialtyARNIBlood PressureWalk TestComorbiditySacubitrilVentricular Function LeftAngiotensin Receptor AntagonistsInternal medicinemedicine6-min walking test Aged Aminobutyrates Angiotensin Receptor Antagonists ARNI Biphenyl Compounds Blood Pressure Comorbidity Dose-Response Relationship Drug Drug Combinations Echocardiography Female Heart failure Humans Left ventricular function Male Middle Aged Prospective Studies Sacubitril/valsartan Stroke Volume Valsartan Ventricular Function Left Walk TestHumansPharmacology (medical)Sacubitril/valsartanProspective Studies6-min walking testAgedPharmacologyHeart FailureEjection fractionDose-Response Relationship DrugCumulative dosebusiness.industryAminobutyratesLeft ventricular functionBiphenyl CompoundsStroke VolumeGeneral MedicineMiddle Agedmedicine.diseaseClinical TrialARNI heart failure left ventricular function 6-minutes walking test Sacubitril/valsartan.Drug CombinationsBlood pressureTolerabilityValsartanEchocardiographyHeart failureCardiologyValsartanFemalebusinessSacubitril Valsartanmedicine.drugEuropean journal of clinical pharmacology
researchProduct

Role of Rate Control and Regularization Through Pacing in Patients With Chronic Atrial Fibrillation and Preserved Ventricular Function: The VRR Study

2006

Aim: High heart rates in chronic atrial fibrillation (CAF) is one of the factors responsible for hemodynamic alterations and may lead to tachycardiomyopathies. The ventricular rate regulation (VRR) study evaluates the effect of ventricular rate regularization in CAF patients with preserved ventricular function, marked ventricular rate variability, and indications for pacemaker (PM) implantation owing to symptomatic pauses. Rate regularization was achieved using VRR algorithm (INSIGNIA® pacemakers, Guidant Corp., St. Paul, MN, USA). Methods: One month after PM implantation, 58 patients followed two 3-month crossover periods (VRR-OFF; VRR-ON) in which the VRR algorithm was randomized and comp…

Malemedicine.medical_specialtyHemodynamicsVentricular Dysfunction LeftHeart RateInternal medicineAtrial FibrillationmedicineHumansChronic atrial fibrillationIn patientLead (electronics)Ventricular functionbusiness.industryCardiac Pacing ArtificialRate controlAtrial fibrillationGeneral MedicineMiddle Agedmedicine.diseaseTreatment OutcomeWalk testAnesthesiaChronic DiseaseTachycardia VentricularCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPacing and Clinical Electrophysiology
researchProduct

Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study

2018

BackgroundSodium-glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the short-term effects of empagliflozin on maximal exercise capacity in these patients. HypothesisWe postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF. MethodsNineteen T2DM patients with symptomatic HF were prospectively included and underwent cardiopulmonary exercise testing before and 30days after initiation of empagliflozin therapy. A mixe…

Malemedicine.medical_specialtyTime FactorsClinical InvestigationsEmpagliflozinRenal functionPilot ProjectsWalk Test030204 cardiovascular system & hematology03 medical and health sciencesExercise Capacity0302 clinical medicineOxygen ConsumptionQuality of lifeGlucosidesInterquartile rangeInternal medicineEmpagliflozinmedicineHumansHypoglycemic Agents030212 general & internal medicineProspective StudiesBenzhydryl CompoundsProspective cohort studyAgedHeart FailureExercise Tolerancebusiness.industryRepeated measures designType 2 Diabetes MellitusGeneral MedicineRecovery of FunctionMiddle AgedEmpagliflozin Exercise Capacity Heart Failuremedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2Heart failureCardiologyQuality of LifeFemaleCardiology and Cardiovascular MedicinebusinessPulmonary Ventilation
researchProduct

Effects of physical and cognitive training on gait speed and cognition in older adults: A randomized controlled trial

2021

Gait speed is a measure of health and functioning. Physical and cognitive determinants of gait are amenable to interventions, but best practices remain unclear. We investigated the effects of a 12-month physical and cognitive training (PTCT) on gait speed, dual-task cost in gait speed, and executive functions (EFs) compared with physical training (PT) (ISRCTN52388040). Community-dwelling older adults, who did not meet physical activity recommendations, were recruited (n = 314). PT included supervised walking/balance (once weekly) and resistance/balance training (once weekly), home exercises (2-3 times weekly), and moderate aerobic activity 150 min/week in bouts of >10 min. PTCT included the…

Malemedicine.medical_specialtyTime FactorsComputer User TrainingWalk TestPhysical Therapy Sports Therapy and RehabilitationWalking030204 cardiovascular system & hematologylaw.inventionExecutive Function03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationRandomized controlled triallawHumansMedicineAerobic exerciseOrthopedics and Sports MedicinePostural BalanceAgedBalance (ability)Aged 80 and overTrail Making Testbusiness.industryResistance TrainingCognition030229 sport sciencesExecutive functionsGaitCognitive trainingExercise TherapyWalking SpeedStroop TestFemaleIndependent Livingbusinesshuman activitiesStroop effectScandinavian Journal of Medicine & Science in Sports
researchProduct

Supervised exercise training in peripheral arterial disease increases vascular shear stress and profunda femoral artery diameter

2016

Background Arteriogenesis is promoted by flow- and pressure-related forces such as tangential wall stress and laminar shear stress. Exercise training (ET) is known to promote arteriogenesis in peripheral arterial disease (PAD) patients. It remains unclear whether supervised ET (SET) promotes arteriogenesis more efficiently than non-SET (nSET). Methods and results Forty PAD patients participated in a SET or nSET training programme ( n = 20 each) and were compared to 20 healthy individuals without any history of cardiovascular events. Femoral artery diameter, flow and velocity were measured by ultrasound. Tangential wall stress and laminar shear stress were calculated for femoral arteries. Fo…

Malemedicine.medical_specialtyTime FactorsEpidemiologyArterial diseaseCollateral CirculationNeovascularization PhysiologicPilot ProjectsWalk TestWalkingFemoral artery030204 cardiovascular system & hematologyArtery morphogenesisPeripheral Arterial Disease03 medical and health sciencesWalking distance0302 clinical medicinemedicine.arteryInternal medicinemedicineShear stressHumansAnkle Brachial Index030212 general & internal medicineAgedUltrasonographyExercise Tolerancebusiness.industryUltrasoundMiddle AgedExercise TherapySurgeryPeripheralFemoral ArteryTreatment OutcomeRegional Blood FlowCase-Control StudiesCardiologyFemaleStress MechanicalArteriogenesisCardiology and Cardiovascular MedicinebusinessEuropean Journal of Preventive Cardiology
researchProduct

Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study

2018

Background: Impaired exercise capacity is the most disabling symptom in patients with heart failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced long-term morbidity and mortality over enalapril in HFrEF, its effects on short-term functional capacity remain uncertain. We sought to evaluate the effects of sacubilril/valsartan on a 30-day six-minute walk test in eligible patients with HFrEF. Methods and results: From November 1, 2016 to February 1, 2017, a total of 58 stable symptomatic patients with HFrEF were eligible for sacubitril/valsartan and underwent 6-MWT before and 30 days after initiation of sacubitril/valsartan therapy. A mixed-effects model …

Malemedicine.medical_specialtyTime FactorsTetrazolesPilot ProjectsWalk Test030204 cardiovascular system & hematologySacubitrilCohort Studies03 medical and health sciencesAngiotensin Receptor AntagonistsElectrocardiography0302 clinical medicineInternal medicineExercise capacityMedicineHumans6-minute walk test030212 general & internal medicineEnalaprilProspective StudiesSacubitril/valsartanAgedAged 80 and overEjection fractionExercise Tolerancebusiness.industryAminobutyratesBiphenyl CompoundsExercise capacityMiddle Agedmedicine.diseaseHeart failure with reduced ejection fractionDrug CombinationsTreatment OutcomeValsartanHeart failureCardiologyValsartanFemaleCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drug
researchProduct

Are first ventilatory threshold and 6-minute walk test heart rate interchangeable? A pilot study in healthy elderlies and cardiac patients

2015

International audience; BACKGROUND: Heart rate (HR) at the ventilatory threshold (VT) is often used to prescribe exercise intensity in cardiac rehabilitation. Some studies have reported no significant difference between HR at VT and HR measured at the end of a 6-min walk test (6-MWT) in cardiac patients. The aim of this work was to assess the potential equivalence between those parameters at the individual level. METHOD: Three groups of subjects performed a stress test and a 6-MWT: 22 healthy elderlies (GES, 77 +/- 3.7 years), 10 stable coronary artery disease (CAD) patients (GMI, 50.9 +/- 4.2 years) and 30 patients with chronic heart failure (GHF, 63.3 +/- 10 years). We analyzed the correl…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPilot ProjectsWalk TestCoronary Artery Disease[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicineOxygen Consumption[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHeart RateInternal medicineHeart ratemedicineHumans6-minute walk testOrthopedics and Sports Medicineventilatory tresholdAgedHeart FailureRehabilitationExercise Tolerancebusiness.industry[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyRehabilitationwalk testsMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseConfidence intervalHealthy VolunteersHeart failureCardiologyPhysical therapyExercise intensityFemaleVentilatory thresholdbusinessPulmonary Ventilationhuman activities030217 neurology & neurosurgeryperformanceAnnals of Physical and Rehabilitation Medicine
researchProduct

Walking Speed as an Alternative Measure of Functional Status in Patients with Lumbar Spinal Stenosis

2019

Objective The main objective was to compare estimated walking perimeter (WP) and actual WP during a free walking test (6-minute walk test [6MWT]) in patients with lumbar spinal stenosis (LSS). The second objective was to describe the correlation between measured gait parameters and functional parameters. Methods This was a single-center prospective study including 38 patients with symptomatic LSS (23 men, 15 women; mean age, 69.3 ± 7.9 years). The intervention was the 6MWT. For the main outcome measure, patients were first asked to verbally estimate their WP. Then, WP was evaluated using a 6MWT at a self-selected speed. In the absence of need to stop, and if a distance of 500 m was not reac…

Malemedicine.medical_specialty[SDV]Life Sciences [q-bio]Walk TestPerimeter03 medical and health sciencesSpinal Stenosis0302 clinical medicineQuality of lifeInterquartile rangeBack painmedicineHumansProspective StudiesAgedLumbar Vertebraebusiness.industryLumbar spinal stenosismedicine.diseaseGaitWalking SpeedOswestry Disability IndexPreferred walking speed030220 oncology & carcinogenesisPhysical therapyFemaleSurgeryNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgeryWorld Neurosurgery
researchProduct

Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report.

2021

Background and objectives: The aim of this study was to report a case of a patient with Charcot-Marie-Tooth disease type 2 (CMT2) treated with epigallocatechin gallate (EGCG) for 4 months in order to assess its therapeutic potential in CMT2. Materials and Methods: The study included a brother and a sister who have CMT2. The sister received 800 mg of EGCG for 4 months, while her brother received placebo for the same period of time. Both participants were assessed before and after daily administration by means of anthropometry; analysis of inflammatory and oxidation markers of interleukin-6 (IL-6) and paraoxonase 1 (PON1) in the blood sample; and motor tests: 2-min walk test (2MWT), 10-m walk…

Malemedicine.medical_specialtyepigallocatechin gallateCase ReportWalk TestDiseaseEpigallocatechin gallatePlaceboCatechinchemistry.chemical_compoundTooth diseaseCharcot-Marie-Tooth DiseaseInternal medicineMedicineHumansCharcot-Marie-Tooth disease type 2lcsh:R5-920IL-6biologyHand Strengthbusiness.industrymotor activityAryldialkylphosphataseParaoxonaseparaoxonase 1General MedicineAnthropometryPON1chemistryWalk testbiology.proteinFemalebusinesslcsh:Medicine (General)
researchProduct